No abstract available.
Female ; Menstrual Cycle* ; Pregnancy Rate* ; Pregnancy*

No abstract available.
Humans ; Infant, Newborn* ; Respiration, Artificial*

Aneurysm of the vein of Galen is a rare midline arteriovenous malformation, usually presenting with cardiac failure in infancy or with hydrocephalus and raised intracranial pressure in older children. We experienced a case of the vein of Galen aneurysm diagnosed with computed tomographic (CT) features and magnetic resonance image (MRI), a new imaging modality. Our case was a 3 day-old male neonate and had a nonspesific symptom of high fever without cardiac failure. A brief review of related literature was made.
Aneurysm* ; Arteriovenous Malformations ; Cerebral Veins* ; Child ; Fever ; Heart Failure ; Humans ; Hydrocephalus ; Infant, Newborn ; Intracranial Pressure ; Male ; Veins*

No abstract available.
Dinoprost* ; Female ; Laparoscopes* ; Pregnancy ; Pregnancy, Tubal*

BACKGROUND: The vascular endothelial growth factor (VEGF) is known as a potent mediator of brain tumor angio-genesis, vascular permeablity, and glioma growth. This study was designed to study the balance between growth and death signals in different grades of astrocytic tumors. METHODS: Using immunohistochemistry, the relationship between the expression of VEGF and microvessel count and density were evaluated in 62 cases of astrocytic tumors including 33 low grade astrocytomas, 6 anaplastic astrocytomas, and 23 glioblastomas. In order to determine the apoptotic index (AI), the in situ end-labeling method was applied. RESULTS: VEGF was expressed on the tumor cell cytoplasm. Of 62 tumors, 44 (77%) were weak to strong postive for VEGF, but 18 cases were not reactive. VEGF positivity was correlat-ed with WHO grades of the astrocytic tumors; low grade astrocytomas (52%), anaplastic astrocytomas (83%), and glioblastomas (96%). Mean microvessel count and density were significantly higher in VEGF-positive tumors (75.7 and 4.1%) than in VEGF-negative tumors (43.9 and 2.5%). Apoptotic cells were readily found in the astrocytic tumors; the highest value of AI was observed in glioblastomas (8.6%) and the lowest in anaplastic astrocytomas (1.9%). It seemed that the grade of malignancy was not related with AI values. CONCLUSIONS: These results suggest that VEGF promotes angiogenesis with tumor cell growth against apoptotic cell death in the human astrocytomas.
Apoptosis* ; Astrocytoma ; Brain Neoplasms ; Cell Death ; Cytoplasm ; Glioblastoma ; Glioma ; Humans ; Immunohistochemistry ; Microvessels ; Vascular Endothelial Growth Factor A*

No abstract available.
Vena Cava, Superior*

Cavernous lymphangioma in mediastinum is a rare congenital malformation of lymphatic system and is caused by lack of adequate drainage from the sequestrated lymphatic vessels to the venous system due to insufficiency or atresia of the efferent lymphatic channels The authors experienced 10 month-old male patient with cavernous lymphangioma in mediastinum documented by chest CT and open biopsy The review of the literature was made briefly.
Biopsy ; Drainage ; Humans ; Infant ; Lymphangioma* ; Lymphatic System ; Lymphatic Vessels ; Male ; Mediastinum* ; Tomography, X-Ray Computed

No abstract available.
Female ; Pregnancy ; Pregnancy, Ectopic* ; Sterilization, Tubal*

BACKGROUND/AIMS: It has been reported that the difference in the hepatitis C virus (HCV) genotype due to genetic heterogeneity of HCV influence the clinical features, prognosis of HCV associated liver disease and response to interferon therapy. Prevalence of different genotypes of HCV may also vary between geographic areas. The aim of this study was to examine the relationship between the response to interferon alpha (IFN-a) therapy and HCV genotypes in patients with chronic HCV infection in Taegu and its environs. METHODS: One hundred seventy six patients known to be HCV antibody and HCV-NA positive were evaluated for HCV genotypes by restriction fragment length polymorphism. Among patients who had elevated ALT levels, 67 patients have been investigated for the role of the HCV genotype on disease outcome and the response of IFN-a therapy. RESULTS: Genotype 1b were found in 59.0% of patients (103/176), genotype 2a in 37.5% (66/176). The mode of transmission of HCV infection was guessed as transfusion in genotype 1b, but as parenteral infection in genotype 2a. According to their response to IFN-a therapy, 73 patients were divided into three groups, complete response, 18 (60%) of 30 patients with genotype 2a and 21 (48.8%) of 43 patients with genotype 1b: partial response, 5 (16.7%) of 30 patients with genotype 2a and 7 (16.2%) of 43 patients with genotype 1b: no response, 7 (23.3%) of 30 patients with genotype 2a and 15 (34.9%) of 43 patients with genotype 1b. Good response to IFN-a therapy was observed among patients group showing normal platelet count in patients with genotype 1b and normal GGT in patients with genotype 2a. CONCLUSIONS: The most frequently identified genotype was genotype 1b in Taegu and its environs, followed by genotype 2a. The HCV genotype was not a reliable predictor of response to IFN-a therapy. When a standardized regimen of IFN-a was administered, pretreatment serum platelet counts and GGT level seem to be useful predictor of IFN-a therapy in HCV infection. Further investigations are required in order to establish a correlation between viral factors and therapeutic responses.
Daegu* ; Genetic Heterogeneity ; Genotype* ; Hepacivirus* ; Hepatitis C* ; Hepatitis* ; Humans ; Interferon-alpha ; Interferons ; Liver Diseases ; Platelet Count ; Polymorphism, Restriction Fragment Length ; Prevalence ; Prognosis

Pulmonary hypertension is an uncommon but serious complication of systemic lupus erythematosis (SLE).Usually its outcomes are ominous and may progress to heart failure and even sudden death.The pathophysiology is still unknown, but several mechanisms,such as pneumonitis,vasculitis,thromboembolism or thrombosis in situ have been proposed.There is no definitive therapy for this condition.Although supportive measures with vasodilators remain the mainstay of treatment,the responses are generally disappointing. We describe a case of improvement of pulmonary hypertension in SLE treated with cyclophosphamide pulse therapy as documented by hemodynamic data. Immunosuppressive treatment with cyclophosphamide was effective in this condition,suggested an immune mediated pathogenesis.
Cyclophosphamide* ; Heart Failure ; Hemodynamics ; Hypertension, Pulmonary* ; Lupus Erythematosus, Systemic* ; Thrombosis ; Vasodilator Agents